TD Cowen raised the firm’s price target on Elevance Health (ELV) to $380 from $330 and keeps a Buy rating on the shares. The firm noted the company maintained FY25 guide but FY26 implied lower versus consensus on a more negative MDCD outlook, offset by more upbeat MA expectations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health: Strategic Outlook and EPS Growth Support Buy Rating
- Elevance Health price target lowered to $385 from $395 at Barclays
- Elevance Health Reports Strong Q3 2025 Revenue Growth
- Morning Movers: General Motors and RTX higher following Q3 reports
- Elevance Health reports Q3 adjusted EPS $6.03, consensus $4.94